Nguyen M Hong, Leal Sixto M, Ostrosky-Zeichner Luis, Spec Andrej, Thompson George R, Patterson Thomas F, Baddley John, McMullen Rachel, Shah Drashti, Clancy Cornelius J, McGwin Gerald, Pappas Peter G
Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Department of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA.
Open Forum Infect Dis. 2025 Jul 17;12(7):ofaf331. doi: 10.1093/ofid/ofaf331. eCollection 2025 Jul.
There is no prospective, US multicenter study of COVID-19-associated pulmonary aspergillosis (CAPA). CAPA definitions do not differentiate invasive aspergillosis (IPA) from colonization. Validity of single mycologic test results is unclear.
We performed a prospective 7-center US study of mechanically ventilated adults with COVID-19 (April 2021-May 2022). Mycoses Study Group (MSGERC) CAPA criteria include host and clinical factors, imaging and test results (histopathology; bronchoalveolar lavage [BAL] culture and/or BAL or serum galactomannan-immunoassay). Proven, putative, and unlikely IPA were defined by clinical criteria. CAPA-unlikely IPA criteria included survival or negative autopsy following no/limited antifungal treatment. IPA likelihood was estimated using sensitivity/specificity of tests from autopsy data.
CAPA incidence was 7% (14/212). Independent CAPA risk factors were EORTC/MSGERC host factor and cavitary lesions. Seven percent, 79%, and 14% of CAPA patients had proven, putative, and unlikely IPA, respectively. Respective estimated IPA likelihoods were 84%, 7%-99%, and 1%-8%. Overall, median estimated IPA likelihood was 30%. Patients with CAPA-unlikely IPA had a single positive BAL galactomannan-immunoassay with other negative tests. CAPA mortality (71%) was not impacted by antifungal treatment or significantly different than without CAPA. CAPA incidence was 10% and 16% by European Confederation of Medical Mycology and Public Health Wales definitions, respectively. IPA was unlikely in 75% (6/8) and 57% (13/23) diagnosed by these definitions but not MSGERC.
CAPA is associated with high mortality, but IPA's contribution is unclear. Single positive tests are insufficient for diagnosing CAPA-IPA. IPA likelihood is best estimated by combining test results (both positive and negative).
目前尚无关于新型冠状病毒肺炎相关肺曲霉病(CAPA)的美国多中心前瞻性研究。CAPA的定义并未区分侵袭性曲霉病(IPA)和定植。单一真菌学检测结果的有效性尚不清楚。
我们对2021年4月至2022年5月期间美国7个中心的机械通气成年COVID-19患者进行了一项前瞻性研究。真菌病研究组(MSGERC)的CAPA标准包括宿主和临床因素、影像学和检测结果(组织病理学;支气管肺泡灌洗[BAL]培养和/或BAL或血清半乳甘露聚糖免疫测定)。确诊、疑似和不太可能的IPA根据临床标准定义。CAPA-不太可能的IPA标准包括在未进行/有限抗真菌治疗后存活或尸检阴性。使用来自尸检数据的检测敏感性/特异性估计IPA可能性。
CAPA发病率为7%(14/212)。独立的CAPA危险因素是欧洲癌症研究与治疗组织/真菌病研究组宿主因素和空洞性病变。分别有7%、79%和14%的CAPA患者确诊、疑似和不太可能患有IPA。各自估计的IPA可能性分别为84%、7%-99%和1%-8%。总体而言,估计的IPA可能性中位数为30%。CAPA-不太可能的IPA患者BAL半乳甘露聚糖免疫测定呈单一阳性,其他检测为阴性。CAPA死亡率(71%)不受抗真菌治疗影响,与无CAPA患者相比无显著差异。根据欧洲医学真菌学联合会和威尔士公共卫生的定义,CAPA发病率分别为10%和16%。根据这些定义但不符合MSGERC标准诊断的患者中,75%(6/8)和57%(13/23)不太可能患有IPA。
CAPA与高死亡率相关,但IPA的作用尚不清楚。单一阳性检测不足以诊断CAPA-IPA。通过综合检测结果(阳性和阴性)来估计IPA可能性最为准确。